Member Info for Laura2022

This can easily be blocked so the main instigators may well need to buy a big chunk over the next few days

11. Recommendation

For the reasons noted above, the Directors consider that the Resolutions to be put to the meeting are in

the best interests of the Company and its Shareholders as a whole and therefore unanimously

recommend that you vote in favour of all of the Resolutions to be proposed at the General Meeting, as

the Directors intend to do in respect of their own aggregate holdings of 160,000 Ordinary Shares,

representing approximately 0.08 per cent. of the Company’s issued share capital as of the date of this

Circular.

Yours faithfully,

Jay Bhattacherjee

Non-Executive Chair

This can easily be blocked so the main instigators may well need to buy a big chunk over the next few days

https://www.sdxenergygroup.com/investors/significant-shareholders/

I've bought mine at 1.2-1.4p a month ago newgrange

Good , sound morally upstanding company Bell keeps

Dave Lenigas to jail over Pennpetro fraud?Today 08:33

By Tom Winnifrith

A shocking RNS today lays bare that shareholders in Pennpetro (PPP), especially those taking part in two 12p placings were deceived and misled as to the state of a company that now admits it is facing possible insolvency. It says it is investigating past directors, the fuzz should be investigating. Investors have bee defrauded, surely Lenigas should go to jail or, at the very least, never run a listed company again

Therfore

Feel free to compare/debate ...for example RENX against these facts

OR spend your time on your own stocks

£1.5mln cap

£600-700k cash ,no debt small losses

CE0 salary £72k is 1/4 of AIM average = modest and alligned

Record contracts won June 2023 to June 2024 £1mln

Record revenues going into end of H1 2024 of currently £800-900k (up to Dec 2024)

Only needs about £1.4mln FY revenues end of June 2025 to probably turn to profit

Working in niche A.I software development market worth $blns

New CEO made huge impact in just 9mths

Potentially very large bio statistic contracts to come (words of BOD at last presentation)

Access to EU and USA markets via NASDAQ partners

There are 100s of AIM stocks yet, after a 10yr hibernation you chose to re emerge trying and lying to talk about one company

You've posted 90% on here in 3mths and yet won't debate RENX which is your latest flame, having also.gone quiet on SCE FAB etc

Your motives.are obvious

Feel free to counter the points made last week regarding PYC

Jaari

Which recruitment "shenanigans "?

You've not answered questions on SCE RENX

Nor why your LSE account remained dormant for 10yrs

What a pathetic person

Just received

Here's part of it

Leadership Transition: We began the year with a major milestone as Dr. Peter Sargent stepped into the CEO role, bringing fresh focus to key initiatives like the launch of our Biostatistics offering and the enhancement of our Data Science and Bioinformatics capabilities.

Partnership Highlights: We had the pleasure of building new partnerships and deepening our existing partnerships with Numab Therapeutics AG, Cancer Research UK, and other leading biotech and pharma companies.

Expanding Expertise: In October, we officially launched our Biostatistics service while continuing to strengthen our ability to deliver tailored insights across drug development through expanded Data Science capabilities.

Engaging the Scientific Community: From ENA 2024 to BioEurope, we showcased exciting projects like our precision dosing tool and connected with industry leaders at major events.

Take a closer look at our 2024 highlights here.

The AIM shares de listed last 12mth have 4 things in common

1 large BOD insider holdings of 40%+ which means they've always pulled the strings

2 awful business model

3 excessive salaries

4 awful sectors

Good riddance so proper revenue generating and modest salary companies can thrive in niche markets

Access to capital: Tarak Ramzan, the majority shareholder with a 20.38% shareholding has proposed to provide a £1.0 million loan facility to provide additional liquidity headroom for working capital purposes

Stich ups easy when directors and associates hold 60% +

Company has received irrevocable undertakings to vote in favour of the Resolutions from all Directors and family members of Tarak Ramzan, the Group's founder, including Nusrat Ramzan, Kasim Akram, Omar Aziz, Haris Ramzan and Mussarat Ramzan. In addition the Company has received irrevocable undertakings from Tajveer Gill and Amraj Gill in respect of 21,600,000 Ordinary Shares in which they are legally and beneficially interested. In aggregate, the irrevocable undertakings to vote in favour of the Resolutions set out in the Circular represent approximately 66.74 per cent. of the Company's issued share capital.

Doesn't seem much stock around , will have ore freed up soon from PIP

Yes..Merck was late December and some contracts may what to be finalised before calander year end , so have early next week and the 27th-30th Dec

Now up further due to these directro options

Thanks rivaldo

Happy with buying at 4 5p

IP Group plc - Two quoted life sciences portfolio companies receive cash offers

- Anticipated further £13.8m of cash proceeds

- Intention to use c.20% of proceeds to further increase share buyback programme

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that two quoted companies in its life sciences portfolio have received cash offers.

Intelligent Ultrasound Group plc, in which the Group has a 20.8% holding, received a cash offer from Surgical Science Sweden AB which values the business at approximately £45.2m. As a result, IP Group expects to receive £8.8m of cash for its holding, which would represent an uplift of £4.4m (100%) from the last-reported NAV at 30 June 2024. This will replace the previously anticipated distribution, following the sale of the company's AI business. The Group will provide a further update following completion, which is subject to, among other things, shareholder approval.

In addition, Abliva AB, which discovers and develops medicines for the treatment of mitochondrial disease and in which the Group has a 9.5% stake, received a cash offer from Pharming Technologies BV which values that business at approximately SEK 725.3m (£52.4m*)

I assume this means Lenigas ?

He by all accounts has a very colourful record

Andrey

Very strange u turn

Mr. N. Kumar, OPG's Non-Executive Chairman, commented:

"OPG's business model is robust and strategic to the opportunities in the Indian Power sector. The trend in FY24 continued in FY25 with the supplies to state electricity boards through long-term and short-term contracts. The continued stability in coal prices enabled the company to sustain margins.